IDAAM Publications

Volume 1

January-March 2023

Resealed erythrocytes as a carrier for drug targeting

Akshay R Yadav

Erythrocyte-mediated drug delivery has been reported with therapeutic enzymes and antiviral agents to enhance therapeutic efficacy, minimize side effects, and serve as circulating depots for controlled drug release, drug targeting, parasitic disease treatment, hepatic tumour treatment, and the removal of toxic agents, among other applications. The benefits of using erythrocytes in drug delivery include a high degree of biocompatibility, full biodegradability, lack of toxic substance, controllable life-span, and decreased drug side effects, to name a few. Many medications with various side effects, such as aspirin, steroid, and cancer drugs, are decreased by resealed erythrocytes. Biopharmaceuticals, therapeutically important peptides and proteins, nucleic acid-based biologicals, antigens, and vaccines are just a few of the pharmaceuticals that have recently been targeted for delivery through carrier erythrocytes. Erythrocyte-based drug delivery systems with the potential to provide managed and site-specific drug delivery will be built in the future for disease management. To use the potentials of erythrocytes in passive as well as active drug targeting in diseases like cancer, a significant amount of useful work is needed. Because of their immense capacity, erythrocytes are currently the most effective carriers in novel drug delivery systems. Hence the present article is reviewed about isolation of erythrocytes, method of drug loading and applications of RSE.
Keywords: Resealed Erythrocyte, Hypotonic Hemolysis, Osmotic Fragility, Nanoerythrosomes, Erythrosome.